Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations.

Antimicrobial Agents and Chemotherapy
Yanhui LuCraig W Hendrix

Abstract

Acyclovir pharmacokinetics was evaluated in 68 HIV-seronegative, herpes simplex virus 2 (HSV-2)-seropositive African women, who received a single oral 400-mg dose of acyclovir, with plasma acyclovir concentrations measured over 8 h. Geometric mean peak concentration and area under the concentration-time curve were 0.31 μg/ml and 1.59 h · μg/ml, respectively, 54% and 52% lower than values from non-Africans. Lower acyclovir concentrations may partly explain the reduced acyclovir suppression of HSV-2 genital ulcer recurrence in HPTN 039 African women participants.

Associated Clinical Trials

References

Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·G B ElionH J Schaeffer
Feb 1, 1991·American Journal of Obstetrics and Gynecology·L M FrenkelJ D Connor
Aug 12, 1995·The Veterinary Record·H A BenchaouiQ A McKellar
Mar 15, 2000·Proceedings of the National Academy of Sciences of the United States of America·S HoffmeyerU Brinkmann
Aug 15, 2001·Lancet·E SchaeffelerM Schwab
May 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Christopher P LandowskiGordon L Amidon
Sep 21, 2004·The Journal of Infectious Diseases·Rachna GuptaLawrence Corey
Jan 25, 2005·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Gh BahramiA Kiani
Oct 10, 2006·Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)·Sylwia FarfalStanislawa Bielecka-Grzela
Aug 25, 2007·International Journal of Pharmaceutics·Thomas F PalmbergerAndreas Bernkop-Schnürch
Dec 18, 2007·Clinical Drug Investigation·Hossein AminiAbolhassan Ahmadiani
Mar 14, 2008·The New England Journal of Medicine·Deborah Watson-JonesUNKNOWN Steering and Data Monitoring Committees
Mar 17, 2009·Biochimica Et Biophysica Acta·King Leung Fung, Michael M Gottesman
Mar 11, 2010·The Journal of Infectious Diseases·Jonathan FuchsUNKNOWN HIV Prevention Trials Network 039 Protocol Team
Jul 1, 2011·Annals of Neurology·Gregory L KraussKelly Chuang

❮ Previous
Next ❯

Citations

Aug 1, 2013·The Journal of Infectious Diseases·Andrew MujugiraUNKNOWN Partners in Prevention HSV/HIV Transmission Study Team
Feb 4, 2016·Materials Science & Engineering. C, Materials for Biological Applications·Parisa S Dorraji, Fahimeh Jalali
Feb 16, 2021·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rebecca G NowakPatti E Gravitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.